ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin–angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry

Yong Hoon Kim, Ae Young Her, Myung Ho Jeong, Byeong Keuk Kim, Sung Jin Hong, Seunghwan Kim, Chul Min Ahn, Jung Sun Kim, Young Guk Ko, Donghoon Choi, Myeong Ki Hong, Yangsoo Jang

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Limited data are available comparing the combined effects of statins and renin–an-giotensin system inhibitor (RASI) between patients with ST-segment elevation myocardial infarction (STEMI) and those with non-STEMI (NSTEMI). We compared the effects of statins combined with RASI in STEMI and NSTEMI patients after stent implantation during a 2-year follow-up period. Methods: A total of 21,890 acute myocardial infarction (AMI) patients who underwent successful stent implantation and who received statins with RASI were enrolled. They were separated into the STEMI group (n = 12,490) and the NSTEMI group (n = 9400). The major clinical endpoint was the occurrence of major adverse cardiac events (MACEs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization. Results: Two propensity score-matched groups (5891 pairs, n = 11,782, C-statistic = 0.821) were generated. Even though the cumulative incidences of MACE, Re-MI, total repeat revascularization were similar between the two groups, the cumulative incidences of all-cause death (hazard ratio [HR] 1.407; 95% confidence interval [CI] 1.106–1.790; p = 0.005) and cardiac death (HR 1.311; 95% CI 0.983–1.749; p = 0.046) were significantly higher in the NSTEMI group. Conclusions: In this study, statin with RASI combination therapy was more beneficial to the STEMI patients than to the NSTEMI patients in reducing all-cause death and cardiac death. (Cardiol J 2022; 29, 4: 647–659).

Original languageEnglish
Pages (from-to)647-659
Number of pages13
JournalCardiology Journal
Volume29
Issue number4
DOIs
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Via Medica.

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin–angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry'. Together they form a unique fingerprint.

Cite this